At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 242 enrolled
Drug / intervention
JTX-2011 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor Malignancies
In Brief
A Phase 2 clinical trial evaluating JTX-2011, Nivolumab, and 2 other interventions for Cancer. Completed, enrolled 242 participants across 16 sites.
Detailed Summary
JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedSep 2016
Primary CompletionJul 2020
TodayJul 2026
First PostedSep 16, 2016
Enrollment StartAug 1, 2016
Primary CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9.8 years ago
Interventions
JTX-2011drug
Specified dose on specified days
Nivolumabdrug
Specified dose on specified days
Ipilimumabdrug
Specified dose on specified days
Pembrolizumabdrug
Specified dose on specified days